Differential effects of antihypertensive drugs on renal and glomerular hemodynamics and injury in the chronic nitric-oxide-suppressed rat

American Journal of Nephrology

Volumn 25, Issue 2, 2005, Pages 138-152

  Zhou, Xiaoyan ^a   Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Glomerulosclerosis; Hemodynamics; Nitric oxide synthase inhibition; Rat model

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CILNIDIPINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFONIDIPINE; ENALAPRIL; EPLERENONE; FELODIPINE; HYDROCHLOROTHIAZIDE; IMIDAPRIL; LISINOPRIL; LOSARTAN; MIBEFRADIL; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; QUINAPRIL; RAMIPRIL; THIAZIDE DIURETIC AGENT; VERAPAMIL;

CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ENDOTHELIUM, VASCULAR; HEMODYNAMIC PROCESSES; HYPERTENSION; KIDNEY; KIDNEY GLOMERULUS; MODELS, ANIMAL; NEPHROSCLEROSIS; NITRIC OXIDE; RATS; VASCULAR DISEASES;

EID: 20844457140     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085358     Document Type: Review

References (117)

1. Furchgott RF: The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA 1996;276:1186-1188.
2. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012.
3. Takahashi T: Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. J Gastroenterol 2003;38:421-430.
4. Kone BC: Nitric oxide synthesis in the kidney: Isoforms, biosynthesis, and functions in health. Semin Nephrol 2004;24:299-315.
5. Raij L: Workshop: Hypertension and cardiovascular risk factors: Role of the angiotensin II-nitric oxide interaction. Hypertension 2001;37:767-773.
6. Brand-Schieber E, Pucci M, Nasjletti A: Determinants of renal vasoconstriction after systemic inhibition of nitric oxide synthesis in rats. Am J Physiol 1996;270:R1203-R1207.
7. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T: Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002;40:521-527.
8. Brede M, Roell W, Ritter O, Wiesmann F, Jahns R, Haase A, Fleischmann BK, Hein L: Cardiac hypertrophy is associated with decreased eNOS expression in angiotensin AT2 receptor-deficient mice. Hypertension 2003;42:1177-1182.
9. Rizvi MA, Myers PR: Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J Mol Cell Cardiol 1997;29:1779-1789.
10. Ono H, Ono Y, Takanohashi A, Matsuoka H, Frohlich ED: Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension 2001;38:1300-1306.
11. Zanchi A, Schaad NC, Osterheld MC, Grouzmann E, Nussberger J, Brunner HR, Waeber B: Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol 1995;268:H2267-H2273.
12. Wessels J, Peake P, Pussell BA, Macdonald GJ: Nitric oxide synthase inhibition in a spontaneously hypertensive rat model of diabetic nephropathy. Clin Exp Pharmacol Physiol 1997;24:451-453.
13. Kashiwagi M, Shinozaki M, Hirakata H, Tamaki K, Hirano T, Tokumoto M, Goto H, Kuda S, Fujishima M: Locally activated renin-angiotensin system associated with TGF-beta1 as a major actor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000;11:616-624.
14. Sander M, Hansen J, Victor RG: The sympathetic nervous system is involved in the maintenance but not initiation of the hypertension induced by N(omega)-nitro-L-arginine methyl ester. Hypertension 1997;30:64-70.
15. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992;90:278-281.
16. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R: Chronic inhibition of nitric oxide synthesis: A new model of arterial hypertension. Hypertension 1992;20:298-303.
17. Ono H, Ono Y, Frohlich ED: Nitric oxide synthesis inhibition in spontaneously hypertensive rats: Systemic, renal, and glomerular hemodynamics. Hypertension 1995;26:249-255.
18. Frohlich ED, Arthur C: Corcoran Memorial Lecture: Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension 1997;29:188-193.
19. Verhagen AM, Koomans HA, Joles JA: Predisposition of spontaneously hypertensive rats to develop renal injury during nitric oxide synthase inhibition. Eur J Pharmacol 2001;411:175-180.
20. Barbuto N, Almeida JR, Pereira LM, Mandarim-de-Lacerda CA: Renal cortex remodeling in nitric oxide deficient rats treated with enalapril. J Cell Mol Med 2004;8:102-108.
21. Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Willis GW: Glomerular dynamics and morphology of aged SHR. Hypertension 1995;25:207-213.
22. Dworkin LD, Feiner HD: Glomerular injury in uninephrectomized spontaneously hypertensive rats: A consequence of glomerular capillary hypertension. J Clin Invest 1986;77:797-809.
23. Dworkin LD, Feiner HD, Parker M, Tolbert E: Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991;39:1112-1127.
24. Bidani AK, Griffin KA, Plot W, Schwartz MM: Renal ablation acutely transforms 'benign' hypertension to 'malignant' nephrosclerosis in hypertensive rats. Hypertension 1994;24:309-316.
25. Griffin KA, Picken MM, Churchill M, Churchill P, Bidani AK: Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat. J Am Soc Nephrol 2000;11:497-506.
26. Dworkin LD, Hostetter TH, Rennke HG, Brenner BM: Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. J Clin Invest 1984;73:1448-1461.
27. Dworkin LD, Tolbert E, Recht PA, Hersch JC, Feiner H, Levin RI: Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 1996;27:245-250.
28. Meyer TW, Rennke HG: Progressive glomerular injury after limited renal infarction in the rat. Am J Physiol 1988;254:F856-F862.
29. Loutzenhiser R, Epstein M, Horton C, Sonke P: Reversal by the calcium antagonist nisoldipine of norepinephrine-induced reduction of GFR: Evidence for preferential antagonism of preglomerular vasoconstriction. J Pharmacol Exp Ther 1985;232:382-387.
30. Loutzenhiser R, Epstein M, Horton C: Inhibition by diltiazem of pressure-induced afferent vasoconstriction in the isolated perfused rat kidney. Am J Cardiol 1987;59:72A-75A.
31. Loutzenhiser RD, Epstein M, Fischetti F, Horton C: Effects of amlodipine on renal hemodynamics. Am J Cardiol 1989;64:122I-127I.
32. Carmines PK, Navar LG: Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol 1989;256:F1015-F1020.
33. Inscho EW, Carmines PK, Cook AK, Navar LG: Afferent arteriolar responsiveness to altered perfusion pressure in renal hypertension. Hypertension 1990;15:748-752.
34. Feng MG, Li M, Navar LG: T-type calcium channels in the regulation of afferent and efferent arterioles in rats. Am J Physiol Renal Physiol 2004;286:F331-F337.
35. Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F: Effects of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000;35:775-779.
36. Isshiki T, Nishikimi T, Uchino K, Kardon MB, Frohlich ED: Diltiazem reduces glomerular pressure in spontaneously hypertensive rats. Cardiovasc Drugs Ther 1992;6:91-92.
37. Dworkin LD, Levin RI, Benstein JA, Parker M, Ullian ME, Kim Y, Feiner HD: Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 1990;259:F598-F604.
38. Dworkin LD, Tolbert E, Recht PA, Hersch JC, Feiner H, Levin RI: Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 1996;27:245-250.
39. Griffin KA, Picken MM, Bidani AK: Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995;96:793-800.
40. Griffin KA, Picken MM, Bakris GL, Bidani AK: Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999;55:1849-1860.
41. Griffin KA, Picken M, Bakris GL, Bidani AK: Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension 2001;37:1268-1272.
42. Ribeiro MO, Antunes E, Muscara MN, De Nucci G, Zatz R: Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertension 1995;26:150-155.
43. Navarro-Cid J, Maeso R, Rodrigo E, Munoz-Garcia R, Ruilope LM, Lahera V, Cachofeiro V: Renal and vascular consequences of the chronic nitric oxide synthase inhibition: Effects of antihypertensive drugs. Am J Hypertens 1996;9:1077-1083.
44. Akuzawa N, Nakamura T, Kurashina T, Saito Y, Hoshino J, Sakamoto H, Sumino H, Ono Z, Nagai R: Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis. Am J Hypertens 1998;11:697-707.
45. Mandarim-de-Lacerda CA, Pereira LM: Renal cortical remodelling by NO-synthesis blockers in rats is prevented by angiotensin-converting enzyme inhibitor and calcium channel blocker. J Cell Mol Med 2001;5:276-283.
46. Qiu C, Bruneval P, Roeckel A, Heudes D, Duong Van Huyen JP, Roux S: Mibefradil prevents L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. J Hypertens 1999;17:1489-1495.
47. Watanabe S, Ono H, Ishimitsu T, Matsuoka H, Ono Y, Fujimori T: Calcium antagonist inhibits glomerular cell apoptosis and injuries of L-NAME exacerbated nephrosclerosis in SHR. Hypertens Res 2000;23:683-691.
48. Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T: Role of actions of calcium antagonists on efferent arterioles - With special references to glomerular hypertension. Am J Nephrol 2003;23:229-244.
49. Francischetti A, Ono H, Frohlich ED: Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998;31:795-801.
50. Nakamura Y, Ono H, Frohlich ED: Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. Hypertension 1999;34:273-278.
51. Zhou X, Ono H, Ono Y, Frohlich ED: N- and L-type calcium channel antagonistic effects on glomerular dynamics in L-NAME rats. J Hypertens 2002;20:993-1000.
52. Susic D, Frohlich ED: Nephroprotective effect of antihypertensive drugs in essential hypertension. J Hypertens 1998;16:555-567.
53. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 2000;57:1803-1817.
54. Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: Renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002;136:604-615.
55. Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH: The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994;45:403-410.
56. Ma L, Fogo AB: Role of angiotensin II in glomerular injury. Semin Nephrol 2001;21:544-553.
57. Cao Z, Cooper ME: Role of angiotensin II in tubulointerstitial injury. Semin Nephrol 2001;21:554-562.
58. Gavras I: Bradykinin-mediated effects of ACE inhibition. Kidney Int 1992;42:1020-1029.
59. Vanhoutte PM, Boulanger CM, Mombouli JV: Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol 1995;76:3E-12E.
60. Hilgers KF, Mann JF: ACE inhibitors versus AT1 receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002; 13:1100-1108.
61. Hornig B, Drexler H: Endothelial function and bradykinin in humans. Drugs 1997;54:42-47.
62. Kon V, Fogo A, Ichikava I: Bradykinin causes selective efferent arteriolar dilatation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44:545-550.
63. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-1935.
64. Siragy HM, Carey RM: Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999;33:1237-1242.
65. 2-subtype receptors in the blood pressure lowering effect of losartan in salt-restricted rats. J Hypertens 1999;16:2039-2043.
66. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ: The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: Gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995;92:10663-10667.
67. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T: The angiotensin AT2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-657.
68. Tsuzuki S, Matoba T, Eguchi S, Inagami T: Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Hypertension 1996;28:916-918.
69. 2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol 1996;122:59-67.
70. 2 receptor. Kidney Int 1998;53:92-96.
71. Kuizinga MC, Smits JFM, Arends JW, Daemen MJAP: AT2 receptor blockade reduces cardiac interstitial cell DNA synthesis and cardiac function after rat myocardial infarction. J Mol Cell Cardiol 1998;30:425-434.
72. Taal MW, Brenner BM: ACE-I vs angiotensin II receptor antagonists: Prevention of renal injury in chronic rat models. J Hum Hypertens 1999;13:S51-S56.
73. Noda M, Fukuda R, Matsuo T, Ohta M, Nagano H, Imura Y, Nishikawa K, Shibouta Y: Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. Kidney Int 1997;63:S136-S139.
74. Noda M, Matsuo T, Fukuda R, Ohta M, Nagano H, Shibouta Y, Naka T, Nishikawa K, Imura Y: Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int 1999;56:898-909.
75. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomized controlled trial. Lancet 2003;361:117-124.
76. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000;321:1440-1444.
77. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J: Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-1961.
78. Ferrari P, Marti HP, Pfister M, Frey FJ: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002;20:125-130.
79. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003;63:1094-1103.
80. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH: Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002;17:1019-1024.
81. Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003;14:992-999.
82. Ono H, Ono Y, Frohlich ED: ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension 1996;27:176-183.
83. Zhou X, Ono H, Ono Y, Frohlich ED: Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004;24:242-249.
84. Nakamura Y, Ono H, Zhou X, Frohlich ED: Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in L-NAME/SHR rats. Hypertension 2001;37:1092-1097.
85. Hropot M, Grotsch H, Klaus E, Langer KH, Linz W, Wiemer G, Scholkens BA: Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: Hypertension, cardiac hypertrophy and renal insufficiency. Naunyn Schmiedebergs Arch Pharmacol 1994;350:646-652.
86. G-nitro-L-arginine methyl ester due to converting enzyme inhibition. J Cardiovasc Pharmacol 1996;28:142-148.
87. A receptor antagonist ameliorates nephrosclerosis and left ventricular hypertrophy induced in rat by prolonged inhibition of nitric oxide synthesis. Hypertens Res 1998;21:251-257.
88. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R: Chronic inhibition of nitric oxide synthesis: A new model of arterial hypertension. Hypertension 1992;20:298-303.
89. Jover B, Herizi A, Ventre F, Dupont M, Mimran A: Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension 1993;21:944-948.
90. Verhagen AM, Braam B, Boer P, Grone HJ, Koomans HA, Joles JA: Losartan-sensitive renal damage caused by chronic NOS inhibition does not involve increased renal angiotensin II concentrations. Kidney Int 1999;56:222-231.
91. Kashiwagi M, Shinozaki M, Hirakata H, Tamaki K, Hirano T, Tokumoto M, Goto H, Okuda S, Fujishima M: Locally activated renin-angiotensin system associated with TGF-beta1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000;11:616-624.
92. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG: Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63:1791-1800.
93. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996;98:1063-1068.
94. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-458.
95. Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999;33:232-237.
96. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK: Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-3878.
97. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000;58:1219-1227.
98. Hene RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982;21:98-101.
99. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-1026.
100. Epstein M, Buckalew V Jr, Martinez F, Altamirano J, Roniker B, Kleiman J, Krause S: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002;15:24A.
101. Sato A, Suzuki Y, Shibata H, Saruta T: Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res 2000;23:25-31.
102. Struthers AD: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.
103. Shiigai T, Shichiri M: Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001;37:477-483.
104. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-68.
105. Epstein M: Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. Am J Kidney Dis 2001;37:677-688.
106. Epstein M: Aldosterone and the hypertensive kidney: Its emerging role as a mediator of progressive renal dysfunction: A paradigm shift. J Hypertens 2001;19:829-842.
107. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
108. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
109. Usui M, Ichiki T, Katoh M, Egashira K, Takeshita A: Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 1998;32:527-533.
110. Freis E, Wilson IM: Potentiating effect of chlorothiazide (Diuril) in combination with antihypertensive agents: Preliminary report. Med Ann Dist Columbia 1957;26:468.
111. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
112. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ, Second Australian National Blood Pressure Study Group: A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-592.
113. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-2572.
114. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease. 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
115. Benstein JA, Feiner HD, Parker M, Dworkin LD: Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR. Am J Physiol 1990;258:F1675-F1681.
116. Ono Y, Ono H, Frohlich ED: Hydrochlorothiazide exacerbates nitric oxide blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 1996;14:823-828.
117. de Leeuw PW: Renal function in the elderly: Results from the European Working Party on High Blood Pressure in the Elderly trial. Am J Med 1991;90:45S-49S.